Melanocyte protein PMEL also known as premelanosome protein (PMEL) or silver locus protein homolog (SILV) is a protein that in humans is encoded by the PMELgene. Its gene product may be referred to as PMEL, silver, ME20, gp100 or Pmel17.
PMEL is a 100 kDa type I transmembrane glycoprotein that is expressed primarily in pigment cells of the skin and eye. The transmembrane form of PMEL is modified in the secretory pathway by elaboration of N-linked oligosaccharides and addition and modification of O-linked oligosaccharides. It is then targeted to precursors of the pigment organelle, the melanosome, where it is proteolytically processed to several small fragments. Some of these fragments form non-pathological amyloid that assemble into sheets and form the striated pattern that underlies melanosomal ultrastructure. PMEL cleavage is mediated by several proteases including a proprotein convertase of the furin family, a "sheddase" that might include members of the a disintegrin and metalloproteinase (ADAM) family, and additional proteases in melanosomes or their precursors. After the amyloidogenic region is cleaved, the small remaining integral membrane fragment is digested by γ-secretase.
Guillaume van Niel; Ptissam Bergam; Aurelie Di Cicco; et al. (2015). "Apolipoprotein E Regulates Amyloid Formation within Endosomes of Pigment Cells". Cell Reports. 13 (1): 43–51. doi:10.1016/j.celrep.2015.08.057.
Adema GJ, de Boer AJ, Vogel AM, et al. (1994). "Molecular characterization of the melanocyte lineage-specific antigen gp100.". J. Biol. Chem. 269 (31): 20126–33. PMID7519602.
Maresh GA, Marken JS, Neubauer M, et al. (1994). "Cloning and expression of the gene for the melanoma-associated ME20 antigen.". DNA Cell Biol. 13 (2): 87–95. doi:10.1089/dna.1994.13.87. PMID8179825.
Bailin T, Lee ST, Spritz RA (1996). "Genomic organization and sequence of D12S53E (Pmel 17), the human homologue of the mouse silver (si) locus.". J. Invest. Dermatol. 106 (1): 24–7. doi:10.1111/1523-1747.ep12326976. PMID8592076.
Wagner SN, Wagner C, Schultewolter T, Goos M (1997). "Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy.". Cancer Immunol. Immunother. 44 (4): 239–47. doi:10.1007/s002620050379. PMID9222283.
Curry BJ, Myers K, Hersey P (1998). "Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma.". J. Clin. Oncol. 16 (5): 1760–9. PMID9586889.
Lukowsky A, Bellmann B, Ringk A, et al. (1999). "Detection of melanoma micrometastases in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction.". J. Invest. Dermatol. 113 (4): 554–9. doi:10.1046/j.1523-1747.1999.00719.x. PMID10504440.
Virador V, Matsunaga N, Matsunaga J, et al. (2002). "Production of melanocyte-specific antibodies to human melanosomal proteins: expression patterns in normal human skin and in cutaneous pigmented lesions.". Pigment Cell Res. 14 (4): 289–97. doi:10.1034/j.1600-0749.2001.140410.x. PMID11549113.
Sensi M, Pellegatta S, Vegetti C, et al. (2003). "Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.". Tissue Antigens. 59 (4): 273–9. doi:10.1034/j.1399-0039.2002.590404.x. PMID12135425.